Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
Travere Therapeutics, Inc.
Brad H Rovin; Jonathan Barratt; Hiddo J L Heerspink; Charles E Alpers; Stewart Bieler; Dong-Wan Chae; Ulysses A Diva; Jürgen Floege; Loreto Gesualdo; Jula K Inrig; Donald E Kohan; Radko Komers; Laura Ann Kooienga; Richard Lafayette; Bart Maes; Robert Małecki; Alex Mercer; Irene L Noronha; Se Won Oh; Chen Au Peh; Manuel Praga; Priscila Preciado; Jai Radhakrishnan; Michelle N Rheault; William E Rote; Sydney C W Tang; Vladimir Tesar; Howard Trachtman; Hernán Trimarchi; James A Tumlin; Muh Geot Wong; Vlado Perkovic; DUPRO steering committee and PROTECT Investigators